Kanokudom Sitthichai, Chansaenroj Jira, Suntronwong Nungruthai, Assawakosri Suvichada, Yorsaeng Ritthideach, Nilyanimit Pornjarim, Aeemjinda Ratchadawan, Khanarat Nongkanok, Vichaiwattana Preeyaporn, Klinfueng Sirapa, Thongmee Thanunrat, Srimuan Donchida, Thatsanathorn Thaksaporn, Sudhinaraset Natthinee, Wanlapakorn Nasamon, Honsawek Sittisak, Poovorawan Yong
Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok 10330, Thailand.
Vaccines (Basel). 2023 Mar 1;11(3):570. doi: 10.3390/vaccines11030570.
The aim of this study is to investigate the reactogenicity and immunogenicity of the fourth dose using monovalent mRNA vaccines after different three-dose regimens and to compare the 30 µg BNT162b2 and 50 µg mRNA-1273 vaccines. This prospective cohort study was conducted between June and October 2022. The self-recorded reactogenicity was evaluated on the subsequent 7 days after a fourth dose. The binding and neutralizing activity of antibodies against the Omicron BA.4/5 variants were determined. Overall, 292 healthy adults were enrolled and received BNT162b2 or mRNA-1273. Reactogenicity was mild to moderate and well tolerated after a few days. Sixty-five individuals were excluded. Thus, 227 eligible individuals received a fourth booster dose of BNT162b2 ( = 109) and mRNA-1273 ( = 118). Most participants, regardless of the type of previous three-dose regimens, elicited a significantly high level of binding antibodies and neutralizing activity against Omicron BA.4/5 28 days after a fourth dose. The neutralizing activity against Omicron BA.4/5 between the BNT162b2 (82.8%) and mRNA-1273 (84.2%) groups was comparable with a median ratio of 1.02. This study found that the BNT162b2 and mRNA-1273 vaccines can be used as a fourth booster dose for individuals who were previously immunized with any prior three-dose mix-and-match COVID-19 vaccine regimens.
本研究旨在调查在不同的三剂接种方案后使用单价mRNA疫苗接种第四剂的反应原性和免疫原性，并比较30μg的BNT162b2疫苗和50μg的mRNA-1273疫苗。这项前瞻性队列研究于2022年6月至10月进行。在接种第四剂后的随后7天评估自我记录的反应原性。测定针对奥密克戎BA.4/5变体的抗体的结合和中和活性。总体而言，292名健康成年人入组并接种了BNT162b2或mRNA-1273疫苗。反应原性为轻度至中度，几天后耐受性良好。65人被排除。因此，227名符合条件的个体接受了BNT162b2（n = 109）和mRNA-1273（n = 118）的第四剂加强针。大多数参与者，无论先前三剂接种方案的类型如何，在接种第四剂后28天对奥密克戎BA.4/5产生了显著高水平的结合抗体和中和活性。BNT162b2组（82.8%）和mRNA-1273组（84.2%）针对奥密克戎BA.4/5的中和活性相当，中位数比值为1.02。本研究发现，BNT162b2和mRNA-1273疫苗可作为先前接种过任何三剂混合搭配的COVID-19疫苗方案的个体的第四剂加强针。
